logo

[breadcrumb_custom]

ACAD’s Stock Market Journey: A Year of Growth, Decline, and Uncertainty

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price loss of -24.31% this year. Over the last six months, there has been a stronger performance of -14.96%. The price of ACAD leaped by -13.94% during the last 30 days period. For the last 5-days stocks have slided -4.70%.

Acadia Pharmaceuticals Inc had a pretty favorable run when it comes to the market performance. Over the past year, the company’s stock reached a high of $33.99 on 07/18/23, while the lowest price during the same period was $17.71 on 04/10/23.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

52-week price history of ACAD Stock

A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Acadia Pharmaceuticals Inc’s current trading price is -30.27% away from its 52-week high, while its distance from the 52-week low is 33.82%. The stock’s price range over this timeframe has been between $17.71 and $33.99. The shares of the Healthcare sector company recorded a trading volume of approximately 1.57 million for the day, which was comparatively lower than the average daily volume of 1.83 million over the last three months.

The Connection Between Financial Performance and Market Capitalization

Acadia Pharmaceuticals Inc (ACAD) has experienced a quarterly rise of 7.14% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.89B and boasts a workforce of 513 employees.

How Moving Averages and Trading Volume Data Work Together

Based on Barchart.com data, the company’s moving average over the 100-day period was 25.22, with a change in price of +2.38. Similarly, Acadia Pharmaceuticals Inc recorded 1,659,310 in trading volume during the last 100 days, posting a change of +11.06%.

ACAD’s Debt-to-Equity Ratio: A Comprehensive Review

A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for ACAD stands at 0.11. Similarly, the long-term debt-to-equity ratio is also 0.11.

ACAD Stock Stochastic Average

Acadia Pharmaceuticals Inc’s raw stochastic average for the past 50 days is currently at 5.85%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 15.56%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 44.43% and 43.42%, respectively.

On Key

Related Posts